NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Price, News & Analysis $0.59 -0.06 (-9.20%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Ensysce Biosciences Stock (NASDAQ:ENSC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ensysce Biosciences alerts:Sign Up Key Stats Today's Range$0.57▼$0.6550-Day Range$0.17▼$0.7352-Week Range$0.14▼$2.06Volume1.91 million shsAverage Volume8.43 million shsMarket Capitalization$8.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEnsysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Read More… Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Ensysce Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks4th Percentile Overall ScoreENSC MarketRank™: Ensysce Biosciences scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Ensysce Biosciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ensysce Biosciences are expected to decrease in the coming year, from ($0.83) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnsysce Biosciences has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ensysce Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted43.43% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently increased by 5,514.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted43.43% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently increased by 5,514.50%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News SentimentN/A News SentimentEnsysce Biosciences has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Ensysce Biosciences this week, compared to 1 article on an average week.Search Interest14 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows6 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.90% of the stock of Ensysce Biosciences is held by insiders.Percentage Held by InstitutionsOnly 5.63% of the stock of Ensysce Biosciences is held by institutions.Read more about Ensysce Biosciences' insider trading history. Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ENSC Stock News HeadlinesReviewing Ensysce Biosciences (NASDAQ:ENSC) & Kiniksa Pharmaceuticals (NASDAQ:KNSA)November 18 at 3:08 AM | americanbankingnews.comEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.November 21, 2024 | Genesis Gold Group (Ad)ENSC Improves PositionNovember 13, 2024 | msn.comEnsysce Biosciences Reports Improved Financial ResultsNovember 13, 2024 | markets.businessinsider.comEnsysce Biosciences receives extension to demonstrate Nasdaq complianceNovember 8, 2024 | markets.businessinsider.comEnsysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics SummitOctober 8, 2024 | finance.yahoo.comWhy Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketSeptember 30, 2024 | benzinga.comSee More Headlines ENSC Stock Analysis - Frequently Asked Questions How have ENSC shares performed this year? Ensysce Biosciences' stock was trading at $1.06 on January 1st, 2024. Since then, ENSC stock has decreased by 44.1% and is now trading at $0.5924. View the best growth stocks for 2024 here. How were Ensysce Biosciences' earnings last quarter? Ensysce Biosciences, Inc. (NASDAQ:ENSC) issued its quarterly earnings data on Tuesday, November, 12th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.37. The company earned $3.42 million during the quarter, compared to analyst estimates of $0.25 million. Ensysce Biosciences had a negative trailing twelve-month return on equity of 292.81% and a negative net margin of 179.26%. When did Ensysce Biosciences' stock split? Shares of Ensysce Biosciences reverse split on the morning of Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Ensysce Biosciences' major shareholders? Top institutional investors of Ensysce Biosciences include Anson Funds Management LP (11.15%). View institutional ownership trends. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ensysce Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO). Company Calendar Last Earnings11/12/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/21/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENSC CUSIPN/A CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-179.26% Pretax Margin-179.26% Return on Equity-292.81% Return on Assets-158.83% Debt Debt-to-Equity RatioN/A Current Ratio3.24 Quick Ratio3.24 Sales & Book Value Annual Sales$2.23 million Price / Sales4.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book1.37Miscellaneous Outstanding Shares13,870,000Free Float12,775,000Market Cap$8.95 million OptionableNot Optionable Beta0.63 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ENSC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.